Empagliflozin improves Cognitive impairment in Frail Diabetics with HFpEF
Italy: Empagliflozin a SGLT2 inhibitor improves the cognitive and Physical impairment in frail older adults Heart failure with Preserved Ejection Fraction and Type 2 Diabetes a recent study has found. It is to be noted that this study was published in Journal Diabetes care on March 21 2022.
Empagliflozin is a SGLT2 inhibitor , Which is a newest class of Oral Hypoglycemic agents which includes Canagliflozin and dapagliflozin. Previous studies have shown that frail Patients with Diabetes and Heart failure with Preserved ejection fraction have Higher Risk of Cognitive and Physical impairment.
Avail the ongoing Early Bird Offer from www.medicozcommunity.com
Visit our Official Instagram https://www.instagram.com/medicozcommunity/
NExT Exam 2024 Preparation is now Easier go and grab the Early Bird Offer.
Leave feedback about this